NuCana PLC (NASDAQ:NCNA) – Equities research analysts at William Blair raised their Q3 2019 earnings per share estimates for NuCana in a research report issued on Thursday, August 22nd, Zacks Investment Research reports. William Blair analyst M. Phipps now anticipates that the company will earn ($0.24) per share for the quarter, up from their prior forecast of ($0.34). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for NuCana’s Q4 2019 earnings at ($0.31) EPS, FY2019 earnings at ($0.92) EPS, Q1 2020 earnings at ($0.32) EPS, Q2 2020 earnings at ($0.29) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.32) EPS, FY2020 earnings at ($1.22) EPS, FY2021 earnings at ($3.67) EPS, FY2022 earnings at ($9.85) EPS and FY2023 earnings at ($8.88) EPS.
Other analysts have also recently issued research reports about the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $25.00 target price (down previously from $35.00) on shares of NuCana in a report on Friday, August 23rd. Citigroup set a $25.00 price target on shares of NuCana and gave the stock a “buy” rating in a report on Wednesday, August 21st. BidaskClub upgraded shares of NuCana from a “sell” rating to a “hold” rating in a report on Saturday, August 31st. HC Wainwright initiated coverage on shares of NuCana in a research report on Monday, August 19th. They set a “buy” rating and a $20.00 price objective for the company. Finally, ValuEngine upgraded shares of NuCana from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $19.69.
NCNA stock traded down $0.54 during mid-day trading on Monday, reaching $10.00. The company had a trading volume of 1,903,790 shares, compared to its average volume of 70,127. The firm has a fifty day simple moving average of $8.75 and a 200 day simple moving average of $12.20. NuCana has a fifty-two week low of $4.01 and a fifty-two week high of $25.82. The company has a market capitalization of $345.14 million, a price-to-earnings ratio of -17.54 and a beta of 3.19.
Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new stake in NuCana during the second quarter worth approximately $32,000. Aperio Group LLC acquired a new stake in NuCana during the second quarter worth approximately $39,000. Susquehanna International Group LLP acquired a new stake in NuCana during the second quarter worth approximately $139,000. Rothschild Investment Corp IL raised its holdings in NuCana by 126.1% during the second quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock worth $291,000 after purchasing an additional 15,660 shares in the last quarter. Finally, Asymmetry Capital Management L.P. lifted its position in shares of NuCana by 5.4% during the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after buying an additional 2,346 shares during the last quarter. 36.11% of the stock is currently owned by institutional investors and hedge funds.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.